Brian Lamoreaux News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Brian LaMoreaux, MD: Outcomes Following Discontinuation of Pegloticase Treatment

After a 12-week gap, 5% of patients returned to pegloticase and responded well.

United statesSan diegoBrian lamoreauxAmerican college of rheumatologyHorizon therapeuticsOutcomes following discontinuationPegloticase therapyAmerican collegeRheumatology information system

Brian LaMoreaux, MD: Use and Efficacy Post-Pegloticase Treatment

The most successful outcomes were observed in patients with at least 6 months of pegloticase therapy who promptly began oral therapy within 60 days.

San diegoUnited statesBrian lamoreauxAmerican college of rheumatologyRheumatology network databaseHorizon therapeuticsUrate lowering therapy useEfficacy following pegloticase treatmentAmerican college

Horizon Therapeutics plc: Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology

Horizon Therapeutics plc: Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesTina venturaEimear rigbyBrian lamoreauxErin linnihanAmanda phranerClin rheumatolPatients with uncontrolled gout coExchange commissionProduct communicationsUniversity of alabama at birminghamCorporate communicationsHealth assessment questionnaireKenneth saagClinical immunologyPrescribing information

Horizon Therapeutics (HZNP) Reports Publication of Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA

Horizon Therapeutics (HZNP) Reports Publication of Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTina venturaAmanda phranerErin linnihanClin rheumatolBrian lamoreauxPatients with uncontrolled gout coExchange commissionUniversity of alabama at birminghamProduct communicationsHealth assessment questionnaireHorizon therapeuticsKenneth saagClinical immunologyPrescribing informationGout nurse advocate

Study Demonstrates Increased Benefits of Pegloticase and Methotrexate Cotherapy for Uncontrolled Gout

At month 12, response rate was significantly higher in patients receiving pegloticase and methotrexate when compared with concomitant placebo.

Brian lamoreauxUniversity of alabama at birmingham kenneth saagUniversity of alabama at birminghamKenneth saagClinical immunology